Marker Therapeutics Appoints Steve Elms to its Board of Directors Houston, TX

Marker Therapeutics Appoints Steve

Elms to its Board of Directors

Houston, TX - August 6, 2019 - Marker

Therapeutics, Inc. (Nasdaq:MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation

T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today announced the

appointment of Steve Elms to

its Board of Directors, effective August 6.

"We are pleased to welcome Steve to our Board

of Directors," said Peter L.

Hoang, President & CEO of Marker. "Steve has

built an impressive career, holding numerous leadership positions in the healthcare sector and we look forward to his many

contributions as we continue to advance our pipeline of next-generation T cell-based immunotherapies."

Throughout his career, Mr. Elms has held numerous

leadership roles in the healthcare sector. Mr. Elms currently serves as Managing Partner at Aisling Capital, a leading life

sciences invetment firm. Prior to joining Aisling, he was a Principal in the Life Sciences Investment Banking Group of Chase

H&Q (formerly Hambrecht & Quist), where he was involved in over 60 financing and M&A transactions, helping

clients raise in excess of $3.3 billion in capital. Prior to H&Q, Mr. Elms traded mortgage-backed securities at

Donaldson, Lufkin & Jenrette. His previous healthcare sector experience includes over two years as a pharmaceutical sales

representative for Marion Laboratories and two years as a consultant for The Wilkerson Group. Mr. Elms currently serves as a

director of ADMA Biologics, Ajax Health II and Zosano Pharma and and was previously chairman of the board of LOXO Oncology. He

also serves on the INVO Board at Northwestern University. Mr. Elms received his M.B.A. from the Kellogg Graduate School of

Management at Northwestern University and his B.A. in Human Biology from Stanford University.

About Marker Therapeutics, Inc.

Marker Therapeutics, Inc. is a clinical-stage immuno-oncology

company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies

and solid tumor indications. Marker's cell therapy technology is based on the selective expansion of non-engineered, tumor-specific

T cells that recognize tumor associated antigens (i.e. tumor targets) and kill tumor cells expressing those targets. This population

of T cells is designed to attack multiple tumor targets following infusion into patients and to activate the patient's immune

system to produce broad spectrum anti-tumor activity. Because Marker does not genetically engineer its T cells therapies, we believe

that our product candidates will be easier and less expensive to manufacture, with reduced toxicities, compared to current engineered

CAR-T and TCR-based approaches, and may provide patients with meaningful clinical benefit. As a result, Marker believes its portfolio

of T cell therapies has a compelling product profile, as compared to current gene-modified CAR-T and TCR-based therapies.

Marker is also advancing a number of innovative peptide- and

gene-based immuno-therapeutics for the treatment of metastatic solid tumors, including the Folate Receptor Alpha program (TPIV200)

for breast and ovarian cancers and the HER2/neu program (TPIV100/110) for breast cancer, currently in Phase 2 clinical trials.

To receive future press releases via email, please visit: https://markertherapeutics.com/email-alerts/

Statement Disclaimer

release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform

Act of 1995. Statements in this news release concerning the Company's expectations, plans, business outlook or future performance,

and any other statements concerning assumptions made or expectations as to any future events, conditions, performance or other

matters, are "forward-looking statements." Forward-looking statements include statements regarding our intentions,

beliefs, projections, outlook, analyses or current expectations concerning, among other things: our research and development activities

relating to our non-engineered multi-tumor antigen specific T cell therapies; our TPIV200 and TPIV100/110 programs; the effectiveness

of these programs or the possible range of application and potential curative effects and safety in the treatment of diseases;

and, the timing and success of our clinical trials, as well as clinical trials conducted by our collaborators. Forward-looking

statements are by their nature subject to risks, uncertainties and other factors which could cause actual results to differ materially

from those stated in such statements. Such risks, uncertainties and factors include, but are not limited to the risks set forth

in the Company's most recent Form 10-K, 10-Q and other SEC filings which are available through EDGAR at www.sec.gov. The

Company assumes no obligation to update our forward-looking statements whether as a result of new information, future events or

otherwise, after the date of this press release.